Since this year, a number of Taiwan's biotech companies have announced that they have entered the ADCs (Antibody-Drug Conjugates) market, starting with HoneyBear Biosciences, which invested by the major API manufacturer SCI Pharmtech, and Bora Pharmaceuticals, PharmaEssentia, OBI Pharma and Tanvex BioPharma.

In addition, Formosa Laboratories and EirGenix have been working together for several years on the CDMO market for ADC drugs, with Formosa being responsible for the development of small molecule drugs and linkers and EirGenix for the development of anti-body drugs. Formosa will expand its ADC drug production line next year as the ADC customer's products have reached the late stage of clinical development.

According to Center Ventures, ADC drugs are more target specific than traditional drugs, and only a smaller dose of the drug needs to be administered to the patient to maximise efficacy, so the production scale and set-up costs for ADC drugs are not too large.

Since ADC drugs are made in small quantities with high quality, many domestic biotech drug companies have been investing in them over the past few years.

In addition, Bora Biologics, PharmaEssentia and Tanvex, have also started to actively invest in the development of new ADC drugs since this year, in the hope of creating business opportunities in new drug markets.